The FDA advisory committee met on July 23-24, 2026 and recommended six of seven peptides for the 503A bulk drug substances list. Here are the tallies, the evaluated uses, our evidence grades, and the part most coverage skipped: what the vote does and does not change.
Checked August 15, 2026 against FDA's published meeting materials. FDA has not published official vote tallies, minutes, or a transcript; the tallies below are as reported by attending legal and trade press.
Current status
Recommended, not permitted.
A PCAC recommendation is advisory. FDA must still run notice-and-comment rulemaking, and as of August 15, 2026 it has issued nothing. None of these six peptides became legal to compound because of this vote.
Open FDA meeting pageCommittee recommendation
6 of 7
Six substances were recommended for the 503A bulks list. Emideltide (DSIP) was the only rejection. Every vote was close.
FDA staff position
Against all 7
FDA's own review team proposed that none of the seven be added. The committee voted the other way on six of them.
What it changes today
Nothing yet
A PCAC recommendation is advisory. FDA has not issued a proposed rule, so none of these substances is compoundable under 503A right now.
FDA has published the briefing document introduction, the voting questions, the final meeting roster, and its presentation slides for July 23 and July 24. Summary minutes and a transcript had not been posted as of August 15, 2026. The public docket was FDA-2025-N-6895, opened by the April 16, 2026 Federal Register meeting notice and closed July 22, 2026.
The evaluated use is the use listed on the FDA agenda. It is not a clinical recommendation, and it does not mean the FDA has found the peptide effective for that condition. Each substance was voted on twice - once as a free base, once as an acetate salt - and the two votes were reported as matching.
Committee vote
8 yes - 6 no - 1 abstain
Outcome
Recommended for the list
FDA-evaluated use
Ulcerative colitis
Legal to compound now?
No - FDA has not acted
Evidence grade
Very low human evidence
Strong animal literature and only a few small human reports; no completed modern randomized trial yet.
Committee vote
8 yes - 6 no - 1 abstain
Outcome
Recommended for the list
FDA-evaluated use
Wound healing and inflammatory conditions
Legal to compound now?
No - FDA has not acted
Evidence grade
Preclinical only
Anti-inflammatory mechanism and animal colitis work are plausible; Peptide Garden has found no human clinical trials.
Committee vote
8 yes - 6 no - 1 abstain
Outcome
Recommended for the list
FDA-evaluated use
Wound healing
Legal to compound now?
No - FDA has not acted
Evidence grade
Very low direct evidence
Human studies exist for full-length thymosin beta-4, but not for the short TB-500 fragment sold online.
Committee vote
7 yes - 5 no - 2 abstain
Outcome
Recommended for the list
FDA-evaluated use
Obesity and osteoporosis
Legal to compound now?
No - FDA has not acted
Evidence grade
Minimal human evidence
The mouse and mechanism story is strong; controlled human evidence for native MOTS-c remains essentially absent.
Emideltide / Delta Sleep-Inducing Peptide
Full profile not live yet
Committee vote
6 yes - 7 no - 1 abstain
Outcome
Not recommended - the only rejection
FDA-evaluated use
Opioid withdrawal, chronic insomnia, and narcolepsy
Legal to compound now?
No - FDA has not acted
Evidence grade
Very low, dated evidence
Small older sleep studies exist, but no modern clinical development program or robust contemporary safety package.
Committee vote
8 yes - 5 no - 1 abstain
Outcome
Recommended for the list
FDA-evaluated use
Cerebral ischemia, migraine, and trigeminal neuralgia
Legal to compound now?
No - FDA has not acted
Evidence grade
Low to limited
Clinical use exists in Russia and Ukraine, but there are no FDA-approved indications or Western registration trials.
Epitalon, free base and acetate salt
Full profile not live yet
Committee vote
7 yes - 4 no - 1 abstain
Outcome
Recommended for the list
FDA-evaluated use
Insomnia
Legal to compound now?
No - FDA has not acted
Evidence grade
Very low, limited replication
Older Russian human reports and in-vitro telomere work do not add up to a modern safety or efficacy package.
This is the part worth getting right. A lot of coverage read the vote as peptides being cleared. It was not.
What it does
The committee recommended that FDA place six substances on the 503A bulk drug substances list for the narrow uses it reviewed. If FDA agrees and completes rulemaking, a state-licensed compounding pharmacy could compound them against a patient-specific prescription.
It is the furthest these peptides have ever moved through a formal FDA process.
What it does not do
It is not FDA approval, not a finding that these peptides work, and not a change in the law. FDA has published no proposed rule. Legal commentary generally expects rulemaking to run into 2027 or later, and FDA is free to decline entirely.
It also does not legitimise research-chemical sellers, settle dosing, or establish a safety profile.
FDA's multidisciplinary review team - drawn from the Office of Compounding Quality and Compliance, the Office of New Drugs, and the Office of Pharmaceutical Quality - recommended that none of the seven substances be added. The committee voted the other way on six. That is unusual, and it is why the outcome is less settled than a typical advisory-committee yes.
FDA's slides state plainly that BPC-157 acetate “is not well-characterized.” Reviewers reported having no information on the nature of individual impurities and no impurity limits or testing results for the substances nominated.
Reviewers flagged the potential for immunogenicity in injectable and nasal-spray forms, driven by peptide aggregation and by two classes of impurity: peptide-related (truncations, incomplete couplings) and process-related (residual solvents, coupling reagents, free amino acids).
The meeting opened with an FDA talk on “conflated bulks” and common-name challenges: one trade name can map to different sequences and molecular weights depending on the supplier. It is the exact problem behind TB-500, where the name is used for both a thymosin beta-4 fragment and the full-length protein.
FDA also underlined what bulks-list placement would not carry with it. A compounded preparation is not FDA-approved, is not required to carry labelling with directions for use, is not made under cGMP, and is not subject to mandatory adverse-event reporting. Those four gaps persist whether or not a substance ends up on the list.
We will update this page when FDA moves. Until a proposed rule appears in the Federal Register, nothing about the legal status of these peptides has changed.
Step 1 - awaited
FDA publishes a proposed rule. The agency decides whether to accept the recommendation. It is not obliged to, and its reviewers argued against it.
Step 2 - awaited
Notice-and-comment, then a final rule. The evaluation criteria themselves were set this way, by final rule in February 2019. Only at the end of this does compounding eligibility actually change.
Also expected
A second peptide meeting. Legal reporting from the meeting indicates FDA signalled another PCAC session covering GHK-Cu, Melanotan II, cathelicidin (LL-37), dihexa, and PEG-MGF. No Federal Register notice or date had been published as of August 15, 2026, so treat the timing as unconfirmed.
Evidence grade reflects Peptide Garden's read of human clinical evidence and safety data. PCAC status reflects where a substance sits in the FDA's compounding review workflow. A weak evidence grade can still appear on a PCAC agenda, and a PCAC vote can still leave major clinical questions unanswered.